Department of General Practice, Zhongda Hospital; Institute of Diabetes, School of Medicine, Southeast University, Nanjing, China.
Department of Endocrinology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University; The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, China.
J Diabetes. 2021 Dec;13(12):1025-1033. doi: 10.1111/1753-0407.13217. Epub 2021 Aug 10.
Creatinine-to-cystatin C ratio has attracted substantial interest as a measure to reflect health well-being, but no studies have assessed whether its longitudinal changes are associated with risk of diabetes. We aimed to examine their association, along with the exploration of the relationship of such changes with cardiometabolic control in middle-aged and older adults.
We included a total of 3278 participants aged ≥45 years who provided measurements of creatinine and cystatin C at baseline and 4 years later from the China Health and Retirement Longitudinal Study. Diabetes was diagnosed based on glucose, hemoglobin A1c (HbA1c), medical history, or use of antidiabetic mediations. Odds ratio (OR) and 95% confidence interval (CI) were obtained using logistic regression analyses.
After 4-year follow-up, 272 participants developed diabetes. Larger increases in creatinine-to-cystatin C ratio were associated with lower risk of diabetes. The multivariable-adjusted OR for diabetes per 1 SD increase in creatinine-to-cystatin C ratio was 0.84 (95% CI 0.72-0.98). Compared with participants showing decreases in creatinine-to-cystatin C ratio but increases in body mass index (BMI), those experiencing increases in creatinine-to-cystatin C ratio and decreases in BMI had the largest risk reduction (multivariable-adjusted OR 0.52). Changes in creatinine-to-cystatin C ratio showed inverse correlation with blood pressure, HbA1c, lipids, and C-reactive protein at the 4-year follow-up. Moreover, they also correlated inversely with changes in HbA1c and C-reactive protein (all P ≤ 0.004).
Increases in creatinine-to-cystatin C ratio led to reduced risk of diabetes and may benefit cardiometabolic control.
肌酸酐-胱抑素 C 比值作为反映健康状况的指标引起了广泛关注,但尚无研究评估其纵向变化与糖尿病风险之间的关系。我们旨在研究其相关性,并探讨这种变化与中老年人群中心血管代谢控制的关系。
我们纳入了总共 3278 名年龄≥45 岁的参与者,他们来自中国健康与退休纵向研究,在基线和 4 年后提供了肌酸酐和胱抑素 C 的测量值。糖尿病的诊断基于血糖、糖化血红蛋白(HbA1c)、病史或使用降糖药物。使用逻辑回归分析获得比值比(OR)和 95%置信区间(CI)。
在 4 年的随访中,有 272 名参与者发生了糖尿病。肌酸酐-胱抑素 C 比值的较大增加与较低的糖尿病风险相关。肌酸酐-胱抑素 C 比值每增加 1 个标准差,糖尿病的多变量调整 OR 为 0.84(95%CI 0.72-0.98)。与肌酸酐-胱抑素 C 比值下降但体重指数(BMI)增加的参与者相比,肌酸酐-胱抑素 C 比值增加且 BMI 下降的参与者风险降低最大(多变量调整 OR 0.52)。在 4 年的随访中,肌酸酐-胱抑素 C 比值的变化与血压、HbA1c、血脂和 C 反应蛋白呈负相关。此外,它们与 HbA1c 和 C 反应蛋白的变化也呈负相关(均 P≤0.004)。
肌酸酐-胱抑素 C 比值的增加可降低糖尿病风险,并可能有益于心血管代谢控制。